About Technology Issues FAQ

Links

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.